Amlodipine Besylate
Product Images NDC 10135-526

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Amlodipine Besylate (NDC 10135-526). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Marlex Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Amlodipine Besylate Tablet 01)

Structural Formula (Amlodipine Besylate Tablet 01)
Chemical structure diagram of Amlodipine Besylate, showing its molecular components and bonds.*
FDA Label Image

Figure 1 (Kaplan-Meier Analysis of Composite Clinical Outcomes for Amlodipine Besylate versus Placebo)

Figure 1 (Kaplan-Meier Analysis of Composite Clinical Outcomes for Amlodipine Besylate versus Placebo)
A line graph showing event rates over time in months for two groups labeled Placebo and Amlodipine. The y-axis represents event rate, ranging from 0 to 0.25, and the x-axis represents time up to 24 months. Amlodipine shows a lower event rate compared to Placebo throughout the period. A boxed note displays a P-value of 0.003 and a hazard ratio of 0.691 with a 95% confidence interval of 0.54 to 0.88.*
FDA Label Image

Figure 2 – Effects On Primary Endpoint Of Amlodipine Besylate Versus Placebo Across Sub- Groups (Amlodipine Besylate Tablet 03)

Figure 2 – Effects On Primary Endpoint Of Amlodipine Besylate Versus Placebo Across Sub- Groups (Amlodipine Besylate Tablet 03)
A forest plot comparing hazard ratios with 95% confidence intervals for Amlodipine versus placebo. The chart includes subgroups by age, gender, baseline sitting systolic blood pressure, baseline vessel disease, baseline vessel with stenosis, and PCI stent stratification. The overall patient population sample size is 1315, with additional stratifications shown for each subgroup.*
FDA Label Image

Marlexamlodipine Besylate Tablets2.5 mg*rx Only500 Tablets (Amlodipine Besylate Tablet 04)

Marlexamlodipine Besylate Tablets2.5 mg*rx Only500 Tablets (Amlodipine Besylate Tablet 04)
Amlodipine Besylate tablets packaging label from Marlex Pharmaceuticals Inc. The label indicates a strength of 2.5 mg per tablet and a quantity of 500 tablets. It includes storage instructions, a barcode, and prescription-only designation (Rx only).*
FDA Label Image

Marlexamlodipine Besylate Tablets5 mg*rx Only500 Tablets (Amlodipine Besylate Tablet 05)

Marlexamlodipine Besylate Tablets5 mg*rx Only500 Tablets (Amlodipine Besylate Tablet 05)
A package label for Amlodipine Besylate Tablets, 5 mg strength, manufactured by Marlex Pharmaceuticals Inc. The label shows the medication is for prescription use only (Rx Only) and contains 500 tablets. Storage and handling instructions and a barcode are also visible on the label.*
FDA Label Image

Marlexamlodipine Besylate Tablets10 mg*rx Only1000 Tablets (Amlodipine Besylate Tablet 06)

Marlexamlodipine Besylate Tablets10 mg*rx Only1000 Tablets (Amlodipine Besylate Tablet 06)
Amlodipine Besylate tablets 10 mg, labeled by Marlex Pharmaceuticals Inc. The label indicates a package containing 1000 tablets. Storage instructions specify 15° to 30°C. The label includes dispensing instructions for pharmacists and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.